Triple-Negative Breast Carcinoma — Trials

Triple-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 417
Recruiting: 234
Ph III recruiting: 22
Growth YoY: +2.4%
Industry share: 31%
Top sponsor: Fudan University
Termination share: 47.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 51–64 of 64 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04502680	Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients(EMBRAVE-001)	unknown	Phase 2	100	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	1	Aug 11, 2020	clinicaltrials
NCT03044730	Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery	unknown	Phase 2	30	Northwestern UniversityOTHER